Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Mesoglycan Ingredients & Drug Interactions

by EuroMedica

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Mesoglycan is a dietary supplement by EuroMedica with 1 active ingredient. Its ingredients are commonly taken for vein health and chronic venous insufficiency, leg ulcers, peripheral artery disease and leg pain.Based on those ingredients, 122 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Mesoglycan. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Mesoglycan by EuroMedica

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 1 of its 1 active ingredient.
  • No proprietary blends here — you can verify the dose of every single component.

This product contains a single active ingredient: mesoglycan, a naturally derived compound. The capsule also contains inactive ingredients — microcrystalline cellulose, hydroxypropyl methylcellulose, silica, and an organic rice extract blend — which serve as binders and fillers.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: blood vessel strength and circulation support.
  • We looked for evidence on: Atherosclerosis, Cerebrovascular disease, Chronic venous insufficiency (CVI), Diabetic retinopathy, Hypertension, Peripheral arterial disease (PAD) — and 4 related terms.
  • The strongest evidence on file: Mesoglycan is rated "Possibly Effective" for Cerebrovascular disease (Natural Medicines).
  • Also on file: Mesoglycan is rated "Possibly Effective" for Peripheral arterial disease (PAD), Venous leg ulcers.
  • Also on file: Mesoglycan is rated "Possibly Ineffective" for Stroke, Venous thromboembolism (VTE).

Mesoglycan is possibly effective for cerebrovascular disease, peripheral arterial disease (PAD), and venous leg ulcers. For venous blood clots (VTE) and stroke prevention, the evidence suggests it's possibly ineffective.

The strength of these ratings means the research is mixed or limited, so talk with your doctor about whether it's a reasonable option for your specific condition.

The evidence, ingredient by ingredient Mesoglycan

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Mesoglycan is generally well tolerated by mouth in studies. Common side effects include nausea, vomiting, stomach pain, heartburn, diarrhea, headache, and skin reactions.

One concern: mesoglycan is made from animal tissue collected from slaughterhouses, and there's a potential risk of contamination from diseased organs, though this is not confirmed as a widespread problem. During pregnancy, there isn't enough safety data, so it's best avoided.

The same applies to breastfeeding — safety is unknown. Talk with your doctor or pharmacist before taking it if you're pregnant, planning to become pregnant, or nursing.

Side effects, ingredient by ingredient Mesoglycan

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Mesoglycan.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs.
  • For scale: 122 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Double-check before starting mesoglycan if you take any blood thinners (anticoagulants) such as warfarin, aspirin, clopidogrel, enoxaparin, or heparin, or any clot-dissolving drugs (thrombolytics) — the interaction severity is Moderate. Your doctor or pharmacist can tell you whether the combination is safe for you.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Mesoglycan may be worth considering if you have peripheral artery disease, cerebrovascular disease, or venous leg ulcers and your doctor agrees it's appropriate. If you take any blood thinner or clot-dissolving medication, check with your doctor or pharmacist first — the interaction risk is real, even if the mechanism is unclear.

Avoid it during pregnancy and breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated Apr 23, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Mesoglycan, straight from the product label.

Brand EuroMedica
Barcode (UPC) 367703835033
Net contents 30 Capsule(s)
Market status On market
Date entered into DSLD Apr 23, 2020
DSLD ID 218214
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Gluten Free, Dairy Free, Sugar Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Mesoglycan by EuroMedica, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
30
UPC/BARCODE
367703835033
IngredientAmount% DV
Mesoglycan50 mg--

Other ingredients: Microcrystalline Cellulose, Hydroxypropyl Methylcellulose, Silica, organic Rice extract blend

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Supports blood vessel strength, integrity, and flexibility Provides bio-identical mesoglycan compounds shown to promote complete circulation support Supports healthy blood vessels in the heart, eyes, legs, brain, and throughout the body

Artery strength and healthy circulation

Non-GMO

No sugar, salt, yeast, wheat, gluten, corn, soy, dairy products, artificial coloring, artificial flavoring, or artificial preservatives.

Suggested/Recommended/Usage/Directions

Recommendations: 1 capsule daily. For advanced support increase to 1 capsule twice daily, or as recommended by your healthcare practitioner.

Precautions

If pregnant or nursing, consult a healthcare practitioner before using.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

FDA Statement of Identity

Dietary Supplement

See for yourself

Mesoglycan by EuroMedica label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Mesoglycan by EuroMedica

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Mesoglycan

Interacts with
122 drugs
50 mg per serving Form: Glycosaminoglycans

Mesoglycan is a blend of natural sugar-protein compounds (glycosaminoglycans, including heparan sulfate and dermatan sulfate) taken from animal tissue...

Mesoglycan monograph & interactions

Other (inactive) ingredients: Microcrystalline Cellulose, Hydroxypropyl Methylcellulose, Silica, Organic Rice extract blend. These complete the product’s ingredient list but are not active constituents.

Interaction report

Mesoglycan by EuroMedica Drug Interactions

Want to check YOUR meds against Mesoglycan?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
122Drugs
122 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Mesoglycan with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Mesoglycan2 drug types · 122 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, combined use might increase bleeding risk. However, human evidence suggests that mesoglycan has profibrinolytic activity without affecting coagulation. These agents include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.

Likelihood Possible Evidence B
Thrombolytic Drugs

Theoretically, combined use might increase bleeding risk. These drugs include alteplase (Activase), anistreplase (Eminase), reteplase (Retevase), streptokinase (Streptase), and urokinase (Abbokinase).

Likelihood Possible Evidence B
The maker

Brand information

Manufacturer and brand details for Mesoglycan, from the product label.

EuroMedica

See all EuroMedica products
Name
EuroMedica
Street Address
955 Challenger Dr.
City
Green Bay
State
WI
ZipCode
54311
Phone Number
866-842-7256
Web Address
www.EuroMedicaUSA.com
Pharmacist Counseling Corner

Mesoglycan by EuroMedica: Common Questions

Does Mesoglycan by EuroMedica interact with any medications?
Yes. Based on its ingredients, Mesoglycan has a known interaction with 122 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Mesoglycan contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
What is mesoglycan and what's it supposed to do?
Mesoglycan is a compound derived from animal tissue. The research suggests it may help with blood flow and healing in conditions like peripheral artery disease, cerebrovascular disease, and venous leg ulcers, though the evidence is still developing.
What side effects should I watch for?
The most common ones are nausea, stomach upset, heartburn, diarrhea, and headache. Skin reactions have also been reported. If you notice any of these, let your pharmacist or doctor know.
Is it safe to take mesoglycan if I'm pregnant or breastfeeding?
No, there isn't enough safety data. Mesoglycan is best avoided during pregnancy and while breastfeeding. Talk with your doctor or pharmacist about alternatives if you need treatment during these times.
Should I be concerned about where mesoglycan comes from?
Mesoglycan is made from animal tissue sourced from slaughterhouses. There's a theoretical risk of contamination from diseased organs, though this isn't a confirmed widespread issue. If you have concerns about product sourcing, ask your pharmacist about the specific brand.
Can I take mesoglycan with my blood thinner?
That's a question for your doctor or pharmacist — it depends on which blood thinner you take and your individual health picture. There's a Moderate interaction risk documented, so don't start mesoglycan without checking with them first.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Mesoglycan is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Mesoglycan label
Sources

Sources & How We Checked

Mesoglycan's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 26 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Mesoglycan 26 references
  1. Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
  2. Nationwide alert on hallmark labs injectable adrenal cortex extract. FDA. Available at: www.fda.gov/bbs/topics/NEWS/NEW00539.html
  3. Laurora G, Cesarone MR, Belcaro G, et al. [Control of the progress of arteriosclerosis in high risk subjects treated with mesoglycan. Measuring the intima media]. Minerva Cardioangiol 1998;46:41-7.
  4. Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.
  5. Blardi P, Messa G, Puccetti L, et al. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man]. Recenti Prog Med 1995;86:282-9.
  6. Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. Int J Dermatol 1993;32:368-71. PubMed
  7. Ambrosio LA, Marchese G, Filippo A, et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993;21:138-46. PubMed
  8. Orlandi G, Viapiano F, Massetani R, et al. Clinical-instrumental evaluation of the effects of mesoglycan sulphate in chronic vascular encephalopathy. Acta Neurol (Napoli) 1991;13:255-60.
  9. Abate G, Berenga A, Caione F, et al. [Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease]. Minerva Med 1991;82:101-5.
  10. Prandoni P, Cattelan AM, Carta M. [Long-term sequelae of deep venous thrombosis of the legs. Experience with mesoglycan]. Ann Ital Med Int 1989;4:378-85.
  11. Cazzato G, Zorzon M, Mase G, et al. [Mesoglycan in acute focal cerebral ischemia]. Riv Neurol 1989;59:121-6.
  12. Vittoria A, Messa GL, Frigerio C, et al. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tissue React 1988;10:261-6.
  13. Postiglione A, De Simone B, Rubba P, et al. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia. Pharmacol Res Commun 1984;16:1-8. PubMed
  14. Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001;22:365-72. PubMed
  15. Nenci, G. G., Gresele, P., Ferrari, G., Santoro, L., and Gianese, F. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb.Haemost. 2001;86(5):1181-1187. DOI
  16. Messa, G., Blardi, P., La Placa, G., Puccetti, L., and Ghezzi, A. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study]. Recenti Prog.Med. 1995;86(7-8):272-281.
  17. Laurora, G., Ambrosoli, L., Cesarone, M. R., De Sanctis, M. T., Incandela, L., Marelli, C., and Belcaro, G. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994;36(2):83-86.
  18. Laurora, G., Cesarone, M. R., De Sanctis, M. T., Incandela, L., and Belcaro, G. Delayed arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. J.Cardiovasc.Surg.(Torino) 1993;34(4):313-318.
  19. Pacella E, Pacella F, Turchetti P, et al. A pilot clinical study on the effectiveness of mesoglycan against diabetic retinopathy. Clin Ter. 2012;163(1):19-22.
  20. Viliani T, Scarselli M, Pieri A, Gatti M, Santini M, Pasquetti P. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. Eur J Phys Rehabil Med. 2009;45(1):21-9.
  21. Gossetti B, Antignani PL, Jabbour J, Martinelli O. Flow-mediated dilation benefits of mesoglycan in peripheral artery disease. Int Angiol. 2015;34(4):398-406.
  22. Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61(4):707-9. PubMed
  23. Gallo G, Mistrangelo M, Passera R, et al. Efficacy of mesoglycan in pain control after excisional hemorrhoidectomy: a pilot comparative prospective multicenter study. Gastroenterol Res Pract. 2018;2018:6423895. PubMed
  24. Neri G, Marcelli V, Califano L, Glicover Investigators. Assessment of the effect of mesoglycan in the treatment of audiovestibular disorders of vascular origin. Int J Immunopathol Pharmacol. 2018;32:2058738418773833. PubMed
  25. Valvano A, Bosso G, Apuzzi V, Riccone F, Saccá L, Oliviero U. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome. Atherosclerosis. 2015;243(2):407-13. PubMed
  26. Gallo G, Di Saverio S, Clerico G, et al. Mesoglycan for pain control after open excisional haemorrhoidectomy (MeHAEMO): an observational multicentre study on behalf of the Italian Society of Colorectal Surgery (SICCR). BMC Surg. 2020 Oct 22;20(1):251.

See these in context on the Mesoglycan monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring